Clinical Trial Update: Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

View source ↗

Summary

This clinical trial update evaluates dose reduction of Radotinib as a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukemia, with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Radotinib (radotinib)

Snippet

Sponsor: Il-Yang Pharm. Co., Ltd. | Conditions: Chronic Phase Ph+ Chronic Myeloid Leukemia | Status: RECRUITING